141 related articles for article (PubMed ID: 14980230)
1. Long-term statin safety and efficacy in secondary prevention: can combination therapy improve outcomes?
Wascher TC
Atheroscler Suppl; 2003 Dec; 4(5):11-6. PubMed ID: 14980230
[TBL] [Abstract][Full Text] [Related]
2. [Statins and cerebrovascular events].
Auer J; Berent R; Eber B
Herz; 2002 Dec; 27(8):765-71. PubMed ID: 12574894
[TBL] [Abstract][Full Text] [Related]
3. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
Hennekens CH; Schneider WR
Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
[TBL] [Abstract][Full Text] [Related]
4. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia.
Sharma M; Ansari MT; Abou-Setta AM; Soares-Weiser K; Ooi TC; Sears M; Yazdi F; Tsertsvadze A; Moher D
Ann Intern Med; 2009 Nov; 151(9):622-30. PubMed ID: 19884623
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review.
Gudzune KA; Monroe AK; Sharma R; Ranasinghe PD; Chelladurai Y; Robinson KA
Ann Intern Med; 2014 Apr; 160(7):468-76. PubMed ID: 24514899
[TBL] [Abstract][Full Text] [Related]
6. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
[TBL] [Abstract][Full Text] [Related]
7. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease.
Lafeber M; Spiering W; van der Graaf Y; Nathoe H; Bots ML; Grobbee DE; Visseren FL
Am Heart J; 2013 Aug; 166(2):282-289.e1. PubMed ID: 23895811
[TBL] [Abstract][Full Text] [Related]
8. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project.
Pfeffer MA; Keech A; Sacks FM; Cobbe SM; Tonkin A; Byington RP; Davis BR; Friedman CP; Braunwald E
Circulation; 2002 May; 105(20):2341-6. PubMed ID: 12021218
[TBL] [Abstract][Full Text] [Related]
11. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of statins: instituting treatment early in acute coronary syndrome patients.
Thompson PL
Atheroscler Suppl; 2001 Feb; 2(1):15-9. PubMed ID: 11286151
[TBL] [Abstract][Full Text] [Related]
13. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
14. Nonstatin therapies for management of dyslipidemia: a review.
Sando KR; Knight M
Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
[TBL] [Abstract][Full Text] [Related]
15. Intensive reduction of low-density lipoprotein-cholesterol: implications of recent trials.
Hackam DG
Am J Cardiovasc Drugs; 2006; 6(6):367-71. PubMed ID: 17192126
[TBL] [Abstract][Full Text] [Related]
16. Evidence for the benefit of early intervention with pravastatin for secondary prevention of cardiovascular events.
Arntz HR
Atherosclerosis; 1999 Sep; 147 Suppl 1():S17-21. PubMed ID: 10575058
[TBL] [Abstract][Full Text] [Related]
17. Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach.
Zeymer U; Jünger C; Zahn R; Bauer T; Bestehorn K; Senges J; Gitt A
Curr Med Res Opin; 2011 Aug; 27(8):1563-70. PubMed ID: 21682553
[TBL] [Abstract][Full Text] [Related]
18. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
Lancellotti P; Pierard LA; Scheen AJ
Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
[TBL] [Abstract][Full Text] [Related]
19. The power of statins: aggressive lipid lowering.
Jones PH
Postgrad Med; 2002 Oct; 112(4 Suppl):23-30. PubMed ID: 19667597
[TBL] [Abstract][Full Text] [Related]
20. Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study.
Athyros VG; Mikhailidis DP; Papageorgiou AA; Bouloukos VI; Pehlivanidis AN; Symeonidis AN; Kakafika AI; Daskalopoulou SS; Elisaf M
Platelets; 2005 Mar; 16(2):65-71. PubMed ID: 15823861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
